Core Insights - Silexion Therapeutics Corp. announced positive preclinical data for SIL204, demonstrating significant efficacy in human lung cancer cell lines, particularly those with KRAS G12D mutations [1][4][6] - The company is conducting a new study on an untested KRAS mutation, with results expected soon, which could further validate SIL204 as a potential pan-KRAS treatment [2][3] - Silexion's dual-route administration strategy is progressing, with plans to initiate a Phase 2/3 clinical trial in Q2 2026 for KRAS-driven solid tumors [3] Study Findings - The study showed dose-dependent inhibition in lung cancer cells with KRAS G12D mutations, highlighting SIL204's potential as a versatile therapeutic [4][7] - The lipid-conjugated delivery system enhances SIL204's entry into tumor cells, addressing a significant barrier for siRNA technology [5][6] Market Opportunity - KRAS mutations are prevalent in various cancers, with approximately 90% in pancreatic cancers, 45% in colorectal cancers, and 30% in lung cancers, representing a significant market opportunity [8] - The global treatment market for these cancers exceeds US $30 billion annually, with many KRAS variants challenging to target with conventional therapies, underscoring the potential of Silexion's RNAi-based strategy [8][9] Company Overview - Silexion Therapeutics is focused on developing RNA interference therapies for solid tumors driven by KRAS mutations, with SIL204 as its next-generation candidate showing promise in preclinical studies [10]

Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous ...

NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, announced today it entered into a new $10 million unsecured line of credit facility with Richard E. Uihlein, Chairman of Galectin Board of Directors, and its largest individual stockholder. “Belapectin has the potential to address a significant unmet med ...

SAN JOSE, Calif., July 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting anti-Müllerian hormone receptor, ...

Core Viewpoint - ProKidney Corp. is actively engaging with investors through participation in the H.C. Wainwright 4 Annual Kidney Virtual Conference, highlighting its focus on chronic kidney disease and its innovative cellular therapy approach [1]. Company Overview - ProKidney Corp. is a pioneer in chronic kidney disease treatment through cellular therapy innovations, founded in 2015 after a decade of research [2]. - The company's lead product candidate, rilparencel (REACT), is a first-in-class autologous cellular therapy currently in Phase 2 and Phase 3 studies aimed at preserving kidney function in diabetic patients at high risk of kidney failure [2]. - Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, indicating its potential significance in the treatment landscape [2].

Core Insights - BriaCell Therapeutics Corp. announced the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive, HER2-negative metastatic breast cancer treated with Bria-OTS, a personalized off-the-shelf immunotherapy [1][2]. Group 1: Clinical Results - The first patient in the Bria-OTS study, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung metastasis after four doses of Bria-OTS monotherapy, confirmed at two, four, and six months [2][3]. - The patient has received a total of 12 cycles of Bria-OTS to date, with no treatment-limiting toxicities observed [6]. Group 2: Expert Commentary - Dr. Neal S. Chawla, Principal Investigator for the Bria-OTS study, highlighted the strong single-agent activity in a challenging patient population and expressed eagerness to explore this approach across more patient subtypes and tumors [5]. - Dr. William V. Williams, BriaCell's President and CEO, emphasized the remarkable and durable clinical response, particularly at the lowest dose level, and indicated plans to evaluate Bria-OTS in combination with a checkpoint inhibitor to enhance outcomes for patients with advanced breast cancer [5]. Group 3: About Bria-OTS - Bria-OTS is a next-generation, off-the-shelf personalized immunotherapy based on BriaCell's lead candidate, Bria-IMT, currently in a Phase 1/2a study for metastatic recurrent breast cancer, which includes both monotherapy dose escalation and combination dose expansion cohorts [7].

REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that the abstract titled “Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunRIZE) Of Ersodetug For Hypoglycemia Due To Congenital Hyperinsulinism: Trial In Progress” has been selected for a late-breaking presentation at ENDO 2025 taking place ...

– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., Chair ...

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), a 2:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the treatment of neuro ...

RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. “For more ...